A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

Jen Shi Chen, Yee Chao, Yung Jue Bang, Enrique Roca, Hyun C. Chung, Felipe Palazzo, Yeul Hong Kim, Scott P. Myrand, Brian P. Mullaney, Li J. Shen, Carlos Linn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed - cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75mg/m. In phase I, the initial dose of pemetrexed was 600mg/m, escalated in 100mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed - cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.

Original languageEnglish
Pages (from-to)777-784
Number of pages8
JournalAnti-Cancer Drugs
Volume21
Issue number8
DOIs
Publication statusPublished - 2010 Sep 1
Externally publishedYes

Fingerprint

Pemetrexed
Cisplatin
Stomach
Carcinoma
Methylenetetrahydrofolate Reductase (NADPH2)
Survival
Confidence Intervals
Pharmacogenomic Testing
Pharmacogenetics
Disease-Free Survival
Stomach Neoplasms
Survival Rate

Keywords

  • advanced gastric carcinoma
  • cisplatin
  • MTHFR
  • pemetrexed
  • pharmacogenetics
  • phase I/II clinical trials
  • unresectable

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. / Chen, Jen Shi; Chao, Yee; Bang, Yung Jue; Roca, Enrique; Chung, Hyun C.; Palazzo, Felipe; Kim, Yeul Hong; Myrand, Scott P.; Mullaney, Brian P.; Shen, Li J.; Linn, Carlos.

In: Anti-Cancer Drugs, Vol. 21, No. 8, 01.09.2010, p. 777-784.

Research output: Contribution to journalArticle

Chen, JS, Chao, Y, Bang, YJ, Roca, E, Chung, HC, Palazzo, F, Kim, YH, Myrand, SP, Mullaney, BP, Shen, LJ & Linn, C 2010, 'A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma', Anti-Cancer Drugs, vol. 21, no. 8, pp. 777-784. https://doi.org/10.1097/CAD.0b013e32833cfbca
Chen, Jen Shi ; Chao, Yee ; Bang, Yung Jue ; Roca, Enrique ; Chung, Hyun C. ; Palazzo, Felipe ; Kim, Yeul Hong ; Myrand, Scott P. ; Mullaney, Brian P. ; Shen, Li J. ; Linn, Carlos. / A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. In: Anti-Cancer Drugs. 2010 ; Vol. 21, No. 8. pp. 777-784.
@article{7554c37742ce4b73a26c15aba9271c5c,
title = "A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma",
abstract = "This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed - cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75mg/m. In phase I, the initial dose of pemetrexed was 600mg/m, escalated in 100mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9{\%}). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5{\%} (14.1{\%}, 35.4{\%}), disease control rate 55.9{\%}, median overall survival 11.8 months (95{\%} confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95{\%} confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed - cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.",
keywords = "advanced gastric carcinoma, cisplatin, MTHFR, pemetrexed, pharmacogenetics, phase I/II clinical trials, unresectable",
author = "Chen, {Jen Shi} and Yee Chao and Bang, {Yung Jue} and Enrique Roca and Chung, {Hyun C.} and Felipe Palazzo and Kim, {Yeul Hong} and Myrand, {Scott P.} and Mullaney, {Brian P.} and Shen, {Li J.} and Carlos Linn",
year = "2010",
month = "9",
day = "1",
doi = "10.1097/CAD.0b013e32833cfbca",
language = "English",
volume = "21",
pages = "777--784",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

AU - Chen, Jen Shi

AU - Chao, Yee

AU - Bang, Yung Jue

AU - Roca, Enrique

AU - Chung, Hyun C.

AU - Palazzo, Felipe

AU - Kim, Yeul Hong

AU - Myrand, Scott P.

AU - Mullaney, Brian P.

AU - Shen, Li J.

AU - Linn, Carlos

PY - 2010/9/1

Y1 - 2010/9/1

N2 - This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed - cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75mg/m. In phase I, the initial dose of pemetrexed was 600mg/m, escalated in 100mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed - cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.

AB - This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed - cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75mg/m. In phase I, the initial dose of pemetrexed was 600mg/m, escalated in 100mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed - cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.

KW - advanced gastric carcinoma

KW - cisplatin

KW - MTHFR

KW - pemetrexed

KW - pharmacogenetics

KW - phase I/II clinical trials

KW - unresectable

UR - http://www.scopus.com/inward/record.url?scp=77955231880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955231880&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32833cfbca

DO - 10.1097/CAD.0b013e32833cfbca

M3 - Article

C2 - 20634689

AN - SCOPUS:77955231880

VL - 21

SP - 777

EP - 784

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -